fda bpc-157 warning letter 📢 News: Today, Dyne Therapeutics announced that the company has submitted a BLA to the for z-rostudirsen for individuals living with #Duchenne who are amenable to exon 51 skipping. The company FDA Sends Warning Letters to

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

What it feels like : Constant hunger, especially in the first 13 weeks Cravings for carbohydrates and salty foods Difficulty staying in a caloric deficit How to manage : Dose at night to sleep through the appetite surge Eat higher fiber and protein meals to blunt hunger Stay hydratedghrelin rises when dehydrated Use Greens + Reds for gut satisfaction and micronutrient density Ghrelin receptor activation by MK-677 leads to dose-dependent appetite stimulation, with the effect diminishing over time as tolerance builds. Smith et al., The Journal of Clinical Endocrinology & Metabolism 2

Common reasons Dose too low - may need to increase to therapeutic levels (2.4mg or higher) Not enough time - meaningful results typically take 8-12 weeks at adequate doses Calorie-dense liquid calories bypassing satiety signals - watch smoothies, alcohol, sugary drinks Eating through fullness signals - pay attention to your body's cues Inconsistent dosing schedule - must be same day each week for optimal levels Unrealistic expectations - 1-2 lbs per week is healthy, sustainable weight loss Key Research [1]"Once-weekly cagrilintide for weight management in people with overweight and obesity" Lau DCW et al., 2021 Finding: Phase 2 trial showed cagrilintide at 4.5mg achieved 10.8% weight loss versus 3% with placebo over 26 weeks in 706 participants

10.1371/journal.pone.0162590 41 LueticK.SucicM.VlainicJ.HalleZ